ChemoCentryx to Participate in Two Upcoming Investor Conferences

Avacopan is also in late-stage clinical development for the treatment of Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also …

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *